CJC-1295 and ipamorelin: why the two are discussed together
Two small peptides, two different switches on the same gland — and what the research does and does not show.
TL;DR
- CJC-1295 and ipamorelin act on two separate pituitary receptors that control growth hormone release.
- In a 1990 study in healthy men, GHRH given with an older growth hormone-releasing peptide released more growth hormone than either alone. That study did not test CJC-1295 or ipamorelin.
- Neither is FDA-approved as a finished drug.
What it is
CJC-1295 and ipamorelin are two short peptides (short chains of amino acids, the building blocks that make up proteins). Both nudge the pituitary — a pea-sized gland at the base of the brain — to release more of the body's own growth hormone. They do not replace growth hormone; they are designed to signal the body's own release.
CJC-1295 is a GHRH analog (in plain English: a copy of growth hormone-releasing hormone, the signal the brain normally sends). Ipamorelin is a GHRP (growth hormone-releasing peptide, which mimics ghrelin — the "hunger hormone" — at a specific pituitary receptor).
How it works
Think of the pituitary as a vending machine with two coin slots. Each slot, on its own, dispenses some growth hormone. In a 1990 study in healthy men, using both slots at once — GHRH plus an older growth hormone-releasing peptide — released more growth hormone than the sum of the two given separately (Bowers et al., 1990). That study did not test CJC-1295 or ipamorelin.
Who asks about it
People come to this topic after they see the two named together online and want to know why. Many have read about CJC-1295 alone or ipamorelin alone and assume one is "stronger." The honest answer is that they act on different receptors, and this article cites no human trial of the two together.
What the research says
In healthy men, GHRH given with an older GHRP released more growth hormone than either on its own (Bowers et al., 1990). Ipamorelin is often named in this context because it did not raise cortisol in published animal studies — unlike its older cousins GHRP-2 and GHRP-6.
Claimed effects such as better sleep or body-composition changes have limited published evidence, and they have not been shown for CJC-1295 and ipamorelin together.
What to know
Reported effects include injection-site reactions, a temporary head-rush flush, and vivid dreams. The long-term safety of the two together in people has not been established. Compounded versions are not FDA-approved. As of September 14, 2026, neither CJC-1295 nor ipamorelin is in any FDA 503A category and neither is on the 503A bulks list.
The Halftime POV
The forum-culture framing is misleading. Two receptors in a diagram do not make a proven treatment. The 1990 pairing data are real, but they come from older peptides, and FDA has approved neither CJC-1295 nor ipamorelin.
Related reading:
- CJC-1295 vs sermorelin: comparing two GHRH analogs
- Peptide 101 FAQs
- Peptides for athletic recovery: what the evidence actually supports
FAQ
Q: Why are CJC-1295 and ipamorelin discussed together? A: They act on two different pituitary receptors that both control growth hormone release. In a 1990 study in healthy men, GHRH given with an older growth hormone-releasing peptide released more growth hormone than either alone. That study did not test CJC-1295 or ipamorelin.
Q: Is CJC-1295 the same as growth hormone? A: No. CJC-1295 is a GHRH analog. It tells the pituitary to release the body's own growth hormone. It does not replace it.
Q: Are these peptides FDA-approved? A: Neither CJC-1295 nor ipamorelin is FDA-approved as a finished drug product. Compounded versions are not FDA-approved. As of September 14, 2026, neither is in any FDA 503A category and neither is on the 503A bulks list.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
- Bowers CY et al., "Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone," J Clin Endocrinol Metab (1990)
- Molitch ME, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline — J Clin Endocrinol Metab, 2011
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Why are CJC-1295 and ipamorelin discussed together?
They act on two different pituitary receptors that both control growth hormone release. In a 1990 study in healthy men, GHRH given with an older growth hormone-releasing peptide released more growth hormone than either alone. That study did not test CJC-1295 or ipamorelin.
Is CJC-1295 the same as growth hormone?
No. CJC-1295 is a GHRH analog. It tells the pituitary to release the body's own growth hormone. It does not replace it.
Are these peptides FDA-approved?
Neither CJC-1295 nor ipamorelin is FDA-approved as a finished drug product. Compounded versions are not FDA-approved. As of September 14, 2026, neither is in any FDA 503A category and neither is on the 503A bulks list.
